ArticleHuman vaccines & immunotherapeutics2025
Clinical and economic burden of herpes zoster in Mexico: A retrospective medical chart analysis in a private healthcare setting.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Herpes zoster hospitalization burden in Spain during the initial period of recombinant zoster vaccine implementation.Human vaccines & immunotherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes zoster (HZ) is characterized by a unilateral, painful rash, which in most cases requires medical attention and pharmacological treatment. Several complications, including postherpetic neuralgia (PHN), may increase the burden of illness and healthcare costs. The objective of this study was to evaluate healthcare resource utilization (HCRU), and direct and indirect costs incurred by patients with HZ from a private sector perspective in Mexico. We carried out a retrospective, medical chart review at five private clinics in Mexico (Mexico City, Monterrey, Aguascalientes, Durango City, León Guanajuato). Healthcare data from patients having an episode of HZ between 2018-2022 were extracted and HCRU and health outcomes were captured over a 6-month period following HZ diagnosis. Outcomes and costs were analyzed by PHN status, age category and comorbidity. Overall, 228 patients with HZ were identified; 59% of patients were women and 67% of patients had at least one comorbidity. Seventy-six (33%) patients developed PHN in the overall population, while among people with comorbidities, 39% developed PHN. Eight (4%) patients were hospitalized. Median direct costs per HZ episode were higher in patients with vs without PHN (United States dollars $836 vs $535) and tended to increase with increasing age. Our results show that HZ imposes a significant burden on patients and the private healthcare system, especially on people developing PHN. PHN and increasing age were the principal cost drivers in this study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.